मूलभूत आँकड़े
| CIK | 1011835 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medivation, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| October 11, 2016 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-32836 MEDIVATION, INC. (Exact name of registrant as specified in |
|
| September 28, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 28, 2016 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. |
|
| September 28, 2016 |
S-8 POS 1 d267173ds8pos.htm S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. 333-213023 Registration No. 333-209748 Registration No. 333-199946 Registration No. 333-190482 Registration No. 333-187203 Registration No. 333-157051 Registration No. 333-132983 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendm |
|
| September 28, 2016 |
S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. |
|
| September 28, 2016 |
S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. |
|
| September 28, 2016 |
S-8 POS 1 d267173ds8pos.htm S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. 333-213023 Registration No. 333-209748 Registration No. 333-199946 Registration No. 333-190482 Registration No. 333-187203 Registration No. 333-157051 Registration No. 333-132983 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendm |
|
| September 28, 2016 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of Class of |
|
| September 28, 2016 |
SC 14D9/A 1 d268182dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Tit |
|
| September 28, 2016 |
S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. |
|
| September 28, 2016 |
Pfizer Completes Acquisition of Medivation EX-99.(a)(5)(B) Exhibit (a)(5)(B) For immediate release Media Contact September 28, 2016 Sally Beatty 212-733-6566 Investor Contact Ryan Crowe 212-733-8160 Information Agent Contact: Morrow Sodali 203-658-9400 (Banks & Brokerage Firms) 800-662-5200 (Shareholders) Pfizer Completes Acquisition of Medivation ? Tender offer for all of the outstanding shares of Medivation common stock expired as schedu |
|
| September 28, 2016 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION MEDIVATION, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEDIVATION, INC. I, the undersigned, for the purpose of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, do hereby execute this Amended and Restated Certificate of Incorporation and do hereby certify as follows: ARTICLE I The name of the corporation is Medivation, Inc. (the |
|
| September 28, 2016 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS of MEDIVATION, INC. dated as of September 28, 2016 TABLE OF CONTENTS ARTICLE I OFFICES 1 SECTION 1. REGISTERED OFFICE 1 SECTION 2. OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 SECTION 1. ANNUAL MEETINGS 1 SECTION 2. SPECIAL MEETINGS 1 SECTION 3. VOTING 1 SECTION 4. QUORUM 2 SECTION 5. NOTICE OF MEETINGS 2 SECTION 6. ACTION WITHOUT MEETING 2 |
|
| September 28, 2016 |
S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 28, 2016 Registration No. |
|
| September 23, 2016 |
SC 14D9/A 1 d263468dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Tit |
|
| September 23, 2016 |
Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation EX-99.(a)(5)(A) Exhibit (a)(5)(A) Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation ? Transaction expected to close in the Third-Quarter 2016 September 23, 2016 08:30 AM Eastern Daylight Time NEW YORK?Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with resp |
|
| September 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of Class of Securities |
|
| September 14, 2016 |
EX-99.(a)(1)(L) Exhibit (a)(1)(L) THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT PFE - Pfizer Inc at Morgan Stanley Global Healthcare Conference EVENT DATE/TIME: SEPTEMBER 13, 2016 / 7:30PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ?2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means |
|
| September 14, 2016 |
SC TO-T/A 1 d233348dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.0 |
|
| September 14, 2016 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 58501 |
|
| September 13, 2016 |
EX-99.(a)(14) September 2016 Equity Payout upon Change in Control Privileged and Confidential Exhibit (a)(14) Cautionary Note Regarding Forward-Looking Statements This communication contains forward-looking information related to the proposed acquisition of Medivation by Pfizer that involves substantial risks and uncertainties that could cause actual results to differ materially from those express |
|
| September 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 58501N101 (CUSI |
|
| September 8, 2016 |
SC 14D9/A 1 d253023dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share (Tit |
|
| September 8, 2016 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of Class of |
|
| September 2, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 30, 2016 |
EX-99.(E)(32) Exhibit (e)(32) August 11, 2016 Revised HAND DELIVERY Dear Mohammad, I am pleased to offer you an extension of the Interim Chief Medical Officer role, effective July 1, 2016, through December 31, 2016. During this period you will continue to report to me. You and I will meet regularly to discuss and plan your priorities and progress toward goals in this period. To recognize and compe |
|
| August 30, 2016 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 30, 2016 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of MEDIVATION, INC. a Delaware corporation at $81.50 NET PER SHARE Pursuant to the Offer to Purchase Dated August 30, 2016 by MONTREAL, INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, ONE MINUTE AFTER 11:59 P.M., EASTERN TIME, ON TUESD |
|
| August 30, 2016 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of MEDIVATION, INC. a Delaware corporation at $81.50 NET PER SHARE Pursuant to the Offer to Purchase Dated August 30, 2016 by MONTREAL, INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, ONE MINUTE AFTER 11:59 P.M., EASTERN TIME, ON TUESDAY, SEPTEMB |
|
| August 30, 2016 |
Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock of MEDIVATION, INC. |
|
| August 30, 2016 |
EX-99.(d)(2) Exhibit (d)(2) June 29, 2016 CONFIDENTIAL Pfizer Inc. 235 East 42nd Street New York, NY 10017 Ladies and Gentlemen: In connection with the consideration by Pfizer Inc. (?you?) of a possible negotiated transaction with Medivation, Inc. (the ?Company,? and collectively with you, the ?parties?), the Company may hereafter furnish to you certain information that is proprietary, non-public |
|
| August 30, 2016 |
EX-99.(A)(1)(D) 5 d249052dex99a1d.htm EX-99.(A)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of MEDIVATION, INC. a Delaware corporation at $81.50 NET PER SHARE Pursuant to the Offer to Purchase Dated August 30, 2016 by MONTREAL, INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, ONE MINUTE AF |
|
| August 30, 2016 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of Class of Securities) 58501N10 |
|
| August 30, 2016 |
EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Medivation, Inc. at $81.50 Net Per Share by Montreal, Inc. a wholly-owned subsidiary of Pfizer Inc. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, ONE MINUTE AFTER 11:59 P.M. EASTERN TIME ON TUESDAY, SEPTEMBER 27, 2016, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED. Montr |
|
| August 30, 2016 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely pursuant to the Offer to Purchase, dated August 30, 2016, and the related Letter of Transmittal and any amendments or |
|
| August 29, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share, including associated preferred stock purchase rights (T |
|
| August 29, 2016 |
EX-99.(i) Exhibit (i) August , 2016 Dear Valued Business Partner: I am pleased to share with you some exciting news. Medivation has reached an agreement to be acquired by Pfizer. Upon completion of the proposed transaction, Medivation will be part of Pfizers Innovative Health Business. Together, we believe that Pfizer and Medivation will be a strong force in helping patients and their caregivers |
|
| August 25, 2016 |
EX-99.I Exhibit (i) August , 2016 Dear : As an important voice within our industry, I am pleased to share with you some exciting news. Medivation has reached an agreement to be acquired by Pfizer. Upon completion of the transaction, Medivation will be part of Pfizer?s Innovative Health Business. Together, Pfizer and Medivation will be a strong force in helping patients and their caregivers with in |
|
| August 25, 2016 |
SC14D9C 1 d246810dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share, including associated pref |
|
| August 25, 2016 |
SC14D9C 1 d246810dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share, including associated pref |
|
| August 25, 2016 |
EX-99.I Exhibit (i) August , 2016 Dear : As an important voice within our industry, I am pleased to share with you some exciting news. Medivation has reached an agreement to be acquired by Pfizer. Upon completion of the transaction, Medivation will be part of Pfizer?s Innovative Health Business. Together, Pfizer and Medivation will be a strong force in helping patients and their caregivers with in |
|
| August 23, 2016 |
EX-99.1 Exhibit 99.1 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ? 2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ?Thomson Reuters? and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its |
|
| August 23, 2016 |
SC TO-C 1 d239562dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of C |
|
| August 22, 2016 |
EX-99.I 2 d245635dex99i.htm EX-99.I Exhibit (i) Dear Team, Today is a day of transformation for Medivation. A few minutes ago, we made an announcement that Pfizer intends to acquire Medivation for approximately $14 billion, or $81.50 per share. Pfizer’s offer is a testament to the value you all have created through your dedication and commitment to our company and to the patients we serve. A copy |
|
| August 22, 2016 |
EMPLOYEE Q&A – AUGUST 22, 2016 TOWN HALL Key Messages EX-99.II 3 d245635dex99ii.htm EX-99.II Exhibit (ii) EMPLOYEE Q&A – AUGUST 22, 2016 TOWN HALL Key Messages ● Our Board has approved an offer to be acquired by Pfizer in an agreement that we believe will deliver significant and immediate value to our stockholders and that will provide new opportunities for our employees as part of a larger company: ¡ Purchase price: $81.50 per share of Medivation co |
|
| August 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share, including associated preferred stock purchase rights (Title of |
|
| August 22, 2016 |
EMPLOYEE Q&A – AUGUST 22, 2016 TOWN HALL Key Messages EX-99.II 3 d245635dex99ii.htm EX-99.II Exhibit (ii) EMPLOYEE Q&A – AUGUST 22, 2016 TOWN HALL Key Messages ● Our Board has approved an offer to be acquired by Pfizer in an agreement that we believe will deliver significant and immediate value to our stockholders and that will provide new opportunities for our employees as part of a larger company: ¡ Purchase price: $81.50 per share of Medivation co |
|
| August 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MEDIVATION, INC. (Name of Person Filing Statement) Common Stock, $0.01 par value per share, including associated preferred stock purchase rights (Title of |
|
| August 22, 2016 |
EX-99.I 2 d245635dex99i.htm EX-99.I Exhibit (i) Dear Team, Today is a day of transformation for Medivation. A few minutes ago, we made an announcement that Pfizer intends to acquire Medivation for approximately $14 billion, or $81.50 per share. Pfizer’s offer is a testament to the value you all have created through your dedication and commitment to our company and to the patients we serve. A copy |
|
| August 22, 2016 |
EX-99.1 Acquisition of Medivation August 22, 2016 Exhibit 99.1 Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, Pfizer, Medivation and Pfizer?s planned acquisition of Medivation, including its potential benefits, anticipated earnings accretion and growth rates, Pfizer?s and M |
|
| August 22, 2016 |
Pfizer Tweets (@Pfizer_news), August 22, 2016 EX-99.3 4 d70220dex993.htm EX-99.3 Exhibit 99.3 Pfizer Tweets (@Pfizernews), August 22, 2016 Pfizer To Acquire Medivation on.pfizer.com/2bIk7y4 |
|
| August 22, 2016 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of Class of Securities) 58501N10 |
|
| August 22, 2016 |
EX-99.1 Acquisition of Medivation August 22, 2016 Exhibit 99.1 Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, Pfizer, Medivation and Pfizer?s planned acquisition of Medivation, including its potential benefits, anticipated earnings accretion and growth rates, Pfizer?s and M |
|
| August 22, 2016 |
Pfizer Tweets (@Pfizer), August 22, 2016 EX-99.2 Exhibit 99.2 Pfizer Tweets (@Pfizer), August 22, 2016 Pfizer To Acquire Medivation http://www.pfizer.com/news/press-release/press-release-detail/pfizertoacquiremedivation |
|
| August 22, 2016 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MEDIVATION, INC. (Name of Subject Company) MONTREAL, INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.01 per share (Title of Class of Securities) 58501N10 |
|
| August 22, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commissi |
|
| August 22, 2016 |
EX-99.1 Exhibit 99.1 PFIZER TO ACQUIRE MEDIVATION Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizers Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with addit |
|
| August 22, 2016 |
AMENDMENT NO. 1 TO RIGHTS AGREEMENT EX-4.1 3 d245915dex41.htm EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT THIS AMENDMENT No. 1 (this “Amendment”), dated as of August 20, 2016, amends the Rights Agreement, dated as of December 4, 2006 (the “Rights Agreement”) between Medivation, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as Rig |
|
| August 22, 2016 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: MEDIVATION, INC. a Delaware corporation; PFIZER INC., a Delaware corporation; and MONTREAL, INC., a Delaware corporation Dated as of August 20, 2016 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Company 5 2.2 Effect of the Merger 5 2.3 Closing; Ef |
|
| August 22, 2016 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: MEDIVATION, INC. a Delaware corporation; PFIZER INC., a Delaware corporation; and MONTREAL, INC., a Delaware corporation Dated as of August 20, 2016 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Company 5 2.2 Effect of the Merger 5 2.3 Closing; Ef |
|
| August 22, 2016 |
AMENDMENT NO. 1 TO RIGHTS AGREEMENT EX-4.1 3 d245915dex41.htm EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT THIS AMENDMENT No. 1 (this “Amendment”), dated as of August 20, 2016, amends the Rights Agreement, dated as of December 4, 2006 (the “Rights Agreement”) between Medivation, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as Rig |
|
| August 22, 2016 |
EX-99.1 Exhibit 99.1 PFIZER TO ACQUIRE MEDIVATION Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizers Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with addit |
|
| August 22, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commissi |
|
| August 22, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2016 (August 20, 2016) PFIZER INC. (Exact name of registrant as specified in its charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-3619 13-5315170 (Comm |
|
| August 22, 2016 |
EX-99.1 Exhibit 99.1 For immediate release: Pfizer Contacts: August 22, 2016 Investors: Ryan Crowe 212-733-8160 Media: Joan Campion 212-733-2798 For Medivation: Investors: Anne Bowdidge Senior Director, Investor Relations (650) 218-6900 Media: Samina Bari Vice President, Corporate Communications (415) 275-5893 Pfizer To Acquire Medivation - Propels Pfizer into a leading position in oncology - Medi |
|
| August 22, 2016 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: MEDIVATION, INC. a Delaware corporation; PFIZER INC., a Delaware corporation; and MONTREAL, INC., a Delaware corporation Dated as of August 20, 2016 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Company 5 2.2 Effect of the Merger 5 2.3 Closing; Effective |
|
| August 22, 2016 |
EX-99.1 Exhibit 99.1 For immediate release: Pfizer Contacts: August 22, 2016 Investors: Ryan Crowe 212-733-8160 Media: Joan Campion 212-733-2798 For Medivation: Investors: Anne Bowdidge Senior Director, Investor Relations (650) 218-6900 Media: Samina Bari Vice President, Corporate Communications (415) 275-5893 Pfizer To Acquire Medivation - Propels Pfizer into a leading position in oncology - Medi |
|
| August 22, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2016 (August 20, 2016) PFIZER INC. (Exact name of registrant as specified in its charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-3619 13-5315170 (Comm |
|
| August 22, 2016 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: MEDIVATION, INC. a Delaware corporation; PFIZER INC., a Delaware corporation; and MONTREAL, INC., a Delaware corporation Dated as of August 20, 2016 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Company 5 2.2 Effect of the Merger 5 2.3 Closing; Effective |
|
| August 9, 2016 |
S-8 As filed with the Securities and Exchange Commission on August 9, 2016 Registration No. |
|
| August 9, 2016 |
S-8 As filed with the Securities and Exchange Commission on August 9, 2016 Registration No. |
|
| August 9, 2016 |
CHANGE OF CONTROL SEVERANCE BENEFITS AGREEMENT EX-10.2 Exhibit 10.2 CHANGE OF CONTROL SEVERANCE BENEFITS AGREEMENT This CHANGE OF CONTROL SEVERANCE BENEFITS AGREEMENT (this ?Agreement?) is made as of the day of , by and between Medivation, Inc., a Delaware Corporation (the ?Company?) and [Name] (?Employee?). To the extent that the Employee is employed by a subsidiary of the Company, such subsidiary entity shall be referred to herein as the ?Em |
|
| August 9, 2016 |
CHANGE OF CONTROL SEVERANCE BENEFITS AGREEMENT EX-10.2 Exhibit 10.2 CHANGE OF CONTROL SEVERANCE BENEFITS AGREEMENT This CHANGE OF CONTROL SEVERANCE BENEFITS AGREEMENT (this ?Agreement?) is made as of the day of , by and between Medivation, Inc., a Delaware Corporation (the ?Company?) and [Name] (?Employee?). To the extent that the Employee is employed by a subsidiary of the Company, such subsidiary entity shall be referred to herein as the ?Em |
|
| August 9, 2016 |
Medivation 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-32836 MEDIVATION, INC. |
|
| August 9, 2016 |
Medivation 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-32836 MEDIVATION, INC. |
|
| August 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 9, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Worldwide Net Sales of XTANDI Totaled $595 Million in the Second Quarter of 2016 (+22% vs. Prior Year) - - Second Quarter 2016 U.S. XTANDI Net Sales of $330.3 Million (+11% vs. Prior Year) - - Second Quarter 2016 U.S. XTANDI Underlying Demand Increased 18% vs. Prior Year - - Second Quarter 2016 Collaboration Revenue $2 |
|
| July 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No. |
|
| July 6, 2016 |
EX-99.1 Talazoparib (MDV3800): A Potentially Best-in-Class PARP Inhibitor July 2016 Exhibit 99.1 WELCOME TO MEDIVATION 2 Forward-Looking Statements Forward-looking statements are made throughout this presentation. The forward-looking statements in this presentation include, but are not limited to, estimates and other speculative statements regarding the potential for the PARP inhibitor class in ge |
|
| July 6, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| July 5, 2016 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, fo |
|
| July 5, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION ENTERS INTO CONFIDENTIALITY AGREEMENTS, INCLUDING WITH SANOFI Sanofi to Terminate its Consent Solicitation Board Committed to Delivering Value and Acting in Stockholders? Best Interests SAN FRANCISCO, CA ? July 5, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today announced that it has entered into confidentiality agreements with a number of parties that have expressed in |
|
| July 5, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| June 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No. |
|
| June 24, 2016 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| June 24, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, We are very pleased to share that Glass Lewis, a leading proxy advisory firm that provides recommendations to investors on proxy votes, has recommended that Medivation?s stockholders support our Board of Directors and reject Sanofi?s solicitation efforts. Their report is a ringing endorsement of both our highly experienced Board members, all of whom are tirelessly c |
|
| June 24, 2016 |
EX-99.1 Exhibit 99.1 GLASS LEWIS RECOMMENDS MEDIVATION?S STOCKHOLDERS SUPPORT THE COMPANY?S CURRENT BOARD Medivation Continues to Urge Stockholders to Reject Sanofi?s Self-Serving Solicitation Efforts SAN FRANCISCO, CA ? June 24, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (?Glass Lewis?) recommends that Medivation?s stockhold |
|
| June 24, 2016 |
EX-99.1 Exhibit 99.1 GLASS LEWIS RECOMMENDS MEDIVATION?S STOCKHOLDERS SUPPORT THE COMPANY?S CURRENT BOARD Medivation Continues to Urge Stockholders to Reject Sanofi?s Self-Serving Solicitation Efforts SAN FRANCISCO, CA ? June 24, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (?Glass Lewis?) recommends that Medivation?s stockhold |
|
| June 24, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| June 24, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, We are very pleased to share that Glass Lewis, a leading proxy advisory firm that provides recommendations to investors on proxy votes, has recommended that Medivation?s stockholders support our Board of Directors and reject Sanofi?s solicitation efforts. Their report is a ringing endorsement of both our highly experienced Board members, all of whom are tirelessly c |
|
| June 24, 2016 |
EX-99.2 3 d208883dex992.htm EX-99.2 Exhibit 99.2 Dear Team, We wanted to share with you the stockholder letter we are sending today that corrects the misleading claims Sanofi has made as a part of its efforts to replace our Board of Directors and acquire our company at an opportunistic, low price. A copy of our press release and letter can be found here: http://investors.medivation.com/releasedeta |
|
| June 24, 2016 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| June 24, 2016 |
EX-99.1 Exhibit 99.1 Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi?s Misleading Claims Reiterates Call for Stockholders to Reject Sanofi?s Attempts to Force Through Its Grossly Inadequate Proposal SAN FRANCISCO, CA ? June 23, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today sent a letter to stockholders providing detailed information to correct the misleading claims Sano |
|
| June 24, 2016 |
DEFA14A 1 d208883d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorp |
|
| June 24, 2016 |
EX-99.1 2 d208883dex991.htm EX-99.1 Exhibit 99.1 Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi’s Misleading Claims Reiterates Call for Stockholders to Reject Sanofi’s Attempts to Force Through Its Grossly Inadequate Proposal SAN FRANCISCO, CA – June 23, 2016 – Medivation, Inc. (NASDAQ: MDVN) today sent a letter to stockholders providing detailed information to correc |
|
| June 24, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, We wanted to share with you the stockholder letter we are sending today that corrects the misleading claims Sanofi has made as a part of its efforts to replace our Board of Directors and acquire our company at an opportunistic, low price. A copy of our press release and letter can be found here: http://investors.medivation.com/releasedetail.cfm?ReleaseID=976970 As w |
|
| June 14, 2016 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, fo |
|
| June 13, 2016 |
EX-99.1 Exhibit 99.1 June 13, 2016 Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders Details Medivations Track Record of Creating Enormous Stockholder Value Highlights the Potential of Medivations Blockbuster XTANDI Franchise and Innovative Late Stage Pipeline to Create Significant Additional Value Urges Stockholders to Reject Sanofis Attempts to Facilita |
|
| June 13, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, We wanted to update you on the latest developments with Sanofi?s consent solicitation and give you a sense of what you can expect as the process moves forward. As you will recall, Sanofi commenced a consent solicitation through which it intends to ask our stockholders to approve the replacement of our entire current Board of Directors with Sanofi?s hand-picked nomin |
|
| June 13, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No. |
|
| June 13, 2016 |
DEFA14A 1 d211751d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorp |
|
| June 13, 2016 |
EX-99.1 Exhibit 99.1 June 13, 2016 Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders Details Medivations Track Record of Creating Enormous Stockholder Value Highlights the Potential of Medivations Blockbuster XTANDI Franchise and Innovative Late Stage Pipeline to Create Significant Additional Value Urges Stockholders to Reject Sanofis Attempts to Facilita |
|
| June 13, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, We wanted to update you on the latest developments with Sanofis consent solicitation and give you a sense of what you can expect as the process moves forward. As you will recall, Sanofi commenced a consent solicitation through which it intends to ask our stockholders to approve the replacement of our entire current Board of Directors with Sanofis hand-picked nomin |
|
| June 13, 2016 |
DFAN14A 1 d331417ddfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a party other than the Registrant þ Check the appropriate box: ¨ Preliminary Prox |
|
| June 13, 2016 |
DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 13, 2016 |
DEFC14A 1 d369936ddefc14a.htm DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| June 9, 2016 |
Medivation AMENDMENT NO. 2 TO SCHEDULE 14A Amendment No. 2 to Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: x Preliminary Consent Statement ? Confidential, for Use of the Com |
|
| June 9, 2016 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of |
|
| June 8, 2016 |
DFAN14A 1 d208746ddfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Prox |
|
| June 7, 2016 |
Medivation AMENDMENT NO. 1 TO SCHEDULE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ¨ Filed by a party other than the Registrant x Check the appropriate box: x Preliminary Consent Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 6, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| June 4, 2016 |
Medivation 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2016 |
EX-99.1 Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.1 Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, estimat |
|
| June 4, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2016 |
EX-99.1 Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.1 Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, estimat |
|
| June 2, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| June 2, 2016 |
MEDIVATION SETS RECORD DATE FOR SANOFI’S PROPOSED CONSENT SOLICITATION EX-99.1 Exhibit 99.1 MEDIVATION SETS RECORD DATE FOR SANOFI?S PROPOSED CONSENT SOLICITATION SAN FRANCISCO, CA ? June 1, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company?s stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the ?Sanofi Consen |
|
| June 2, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, As you may have seen, today Sanofi issued a press release requesting that the Medivation Board of Directors set a record date regarding its proposed consent solicitation through which it is seeking stockholder approval to replace all the members of our Board of Directors. In accordance with this request, our Board of Directors set the record date for today, June 1 |
|
| June 2, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, As you may have seen, today Sanofi issued a press release requesting that the Medivation Board of Directors set a record date regarding its proposed consent solicitation ? through which it is seeking stockholder approval to replace all the members of our Board of Directors. In accordance with this request, our Board of Directors set the record date for today, June 1 |
|
| June 2, 2016 |
MEDIVATION SETS RECORD DATE FOR SANOFI’S PROPOSED CONSENT SOLICITATION EX-99.1 Exhibit 99.1 MEDIVATION SETS RECORD DATE FOR SANOFI?S PROPOSED CONSENT SOLICITATION SAN FRANCISCO, CA ? June 1, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company?s stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the ?Sanofi Consen |
|
| June 2, 2016 |
DEFA14A 1 d205026d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorpo |
|
| June 1, 2016 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, fo |
|
| May 27, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION FILES PRELIMINARY CONSENT REVOCATION STATEMENT Board Committed to Stockholders? Best Interests and Continuing to Deliver Significant Value Hostile Consent Solicitation Merely a Tactic to Facilitate Sanofi?s Substantially Inadequate Proposal; Hand-Picked Nominees Have Minimal Biotech Experience SAN FRANCISCO, CA ? May 27, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today |
|
| May 27, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| May 27, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, A few minutes ago, we filed our consent revocation statement with the SEC. The filing details our opposition to Sanofis tactical maneuver to replace our entire Board with its hand-picked nominees to facilitate its substantially inadequate and opportunistically-timed proposal to acquire Medivation. I hope you take a few moments to review our press release, which can |
|
| May 27, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| May 27, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION FILES PRELIMINARY CONSENT REVOCATION STATEMENT Board Committed to Stockholders? Best Interests and Continuing to Deliver Significant Value Hostile Consent Solicitation Merely a Tactic to Facilitate Sanofi?s Substantially Inadequate Proposal; Hand-Picked Nominees Have Minimal Biotech Experience SAN FRANCISCO, CA ? May 27, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today |
|
| May 27, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, A few minutes ago, we filed our consent revocation statement with the SEC. The filing details our opposition to Sanofi?s tactical maneuver to replace our entire Board with its hand-picked nominees to facilitate its substantially inadequate and opportunistically-timed proposal to acquire Medivation. I hope you take a few moments to review our press release, which can |
|
| May 27, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| May 25, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| May 25, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, You may have seen this morning that Sanofi has filed preliminary materials with the SEC in order to prepare to commence a consent solicitation that seeks stockholder approval to replace all the members of Medivations Board of Directors. I wanted to reach out to give you an update and explain what this means, as well as share our press release in response to Sanofi |
|
| May 25, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION URGES STOCKHOLDERS TO REJECT SANOFI?S ATTEMPT TO REPLACE MEDIVATION BOARD OF DIRECTORS Proposed Consent Solicitation a Tactic to Facilitate Sanofi?s Substantially Inadequate Proposal Medivation to Promptly File Consent Revocation Materials SAN FRANCISCO, CA ? May 25, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today urged its stockholders to reject Sanofi?s attempt to re |
|
| May 25, 2016 |
EX-99.1 2 d198245dex991.htm EX-99.1 Exhibit 99.1 MEDIVATION URGES STOCKHOLDERS TO REJECT SANOFI’S ATTEMPT TO REPLACE MEDIVATION BOARD OF DIRECTORS Proposed Consent Solicitation a Tactic to Facilitate Sanofi’s Substantially Inadequate Proposal Medivation to Promptly File Consent Revocation Materials SAN FRANCISCO, CA – May 25, 2016 – Medivation, Inc. (NASDAQ: MDVN) today urged its stockholders to r |
|
| May 25, 2016 |
DEFA14A 1 d198245d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorpo |
|
| May 25, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, You may have seen this morning that Sanofi has filed preliminary materials with the SEC in order to prepare to commence a consent solicitation that seeks stockholder approval to replace all the members of Medivation?s Board of Directors. I wanted to reach out to give you an update and explain what this means, as well as share our press release in response to Sanofi? |
|
| May 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 25, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: x Preliminary Consent Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| May 17, 2016 |
Employee Key Messages for Verbal Delivery by Managers May 16, 2016 EX-99.1 Exhibit 99.1 Employee Key Messages for Verbal Delivery by Managers May 16, 2016 ? We know that you have been reading articles in the news media about the state of Medivation?s future and want to address a few points with you. ? It is our policy not to comment on rumors or speculation. ? When there is news to report to you, we will inform you directly, as appropriate. But, here?s what we ca |
|
| May 17, 2016 |
Medivation 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| May 17, 2016 |
DEFA14A 1 d180010d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorpo |
|
| May 17, 2016 |
Employee Key Messages for Verbal Delivery by Managers May 16, 2016 EX-99.1 Exhibit 99.1 Employee Key Messages for Verbal Delivery by Managers May 16, 2016 ? We know that you have been reading articles in the news media about the state of Medivation?s future and want to address a few points with you. ? It is our policy not to comment on rumors or speculation. ? When there is news to report to you, we will inform you directly, as appropriate. But, here?s what we ca |
|
| May 12, 2016 |
Medivation SANOFI DFAN 14A 5-12-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 12, 2016 |
EX-99.1 Exhibit 99.1 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT MDVN - Medivation Inc at Bank of America Merrill Lynch Health Care Conference EVENT DATE/TIME: MAY 11, 2016 / 3:00PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ?2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is |
|
| May 12, 2016 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2016 |
EX-99.1 Exhibit 99.1 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT MDVN - Medivation Inc at Bank of America Merrill Lynch Health Care Conference EVENT DATE/TIME: MAY 11, 2016 / 3:00PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ?2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is |
|
| May 12, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2016 |
Medivation 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 9, 2016 |
EX-99.1 Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.1 Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, estimat |
|
| May 9, 2016 |
EX-99.1 Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.1 Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, estimat |
|
| May 9, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 6, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, As you all know, we had our quarterly earnings call today. We can only tell you that it was an absolutely resounding success! The first comment in the Q&A from Geoff Meacham of Barclay?s was ?That was a drop-the-mike presentation!?. Anne Bowdidge received more than 120 emails within 30 minutes of our call, and there were several hundred attendees on the call and web |
|
| May 6, 2016 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2016 |
EX-99.1 Exhibit 99.1 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT MDVN - Q1 2016 Medivation Inc Earnings Call EVENT DATE/TIME: MAY 05, 2016 / 8:30PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ?2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior writt |
|
| May 6, 2016 |
EX-99.1 Exhibit 99.1 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT MDVN - Q1 2016 Medivation Inc Earnings Call EVENT DATE/TIME: MAY 05, 2016 / 8:30PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ?2016 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior writt |
|
| May 6, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, As you all know, we had our quarterly earnings call today. We can only tell you that it was an absolutely resounding success! The first comment in the Q&A from Geoff Meacham of Barclay?s was ?That was a drop-the-mike presentation!?. Anne Bowdidge received more than 120 emails within 30 minutes of our call, and there were several hundred attendees on the call and web |
|
| May 6, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2016 |
EX-99.2 Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.2 Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, our ant |
|
| May 6, 2016 |
EX-99.1 Financial and Corporate Update Exhibit 99.1 Speakers David Hung, M.D. – Founder, President and CEO Marion McCourt – Chief Operating Officer Jennifer Jarrett – Chief Financial Officer Mohammad Hirmand, M.D. – Interim Chief Medical Officer Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that |
|
| May 6, 2016 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2016 |
EX-99.2 Delivering Value Now and Into The Future David Hung, M.D. Founder, President and CEO Exhibit 99.2 Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, our ant |
|
| May 6, 2016 |
EX-99.1 Financial and Corporate Update Exhibit 99.1 Speakers David Hung, M.D. – Founder, President and CEO Marion McCourt – Chief Operating Officer Jennifer Jarrett – Chief Financial Officer Mohammad Hirmand, M.D. – Interim Chief Medical Officer Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that |
|
| May 5, 2016 |
Medivation 10-Q (Quarterly Report) mdvn-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: |
|
| May 5, 2016 |
MEDIVATION REITERATES REJECTION OF SANOFI?S SUBSTANTIALLY INADEQUATE PROPOSAL EX-99.2 Exhibit 99.2 MEDIVATION REITERATES REJECTION OF SANOFI?S SUBSTANTIALLY INADEQUATE PROPOSAL SAN FRANCISCO, CA ? May 5, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today reiterated its rejection of Sanofi?s substantially inadequate proposal to acquire the Company for $52.50 per share in cash, following the receipt of a letter from Sanofi. Medivation notes that Sanofi?s letter simply restates an i |
|
| May 5, 2016 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| May 5, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS FULL-YEAR 2016 FINANCIAL GUIDANCE REAFFIRMED - Worldwide Net Sales of XTANDI Totaled $547 Million in the First Quarter of 2016 (+53% vs. Prior Year) - - First Quarter 2016 U.S. XTANDI Unit Demand Increased 33% vs. Prior Year and 7% vs Q4 2015 - - First Quarter 2016 U.S. XTANDI Net Sales of $307.6 Million (+37% vs. Prior Y |
|
| May 5, 2016 |
EX-99.1 Exhibit 99.1 MEDIVATION REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS FULL-YEAR 2016 FINANCIAL GUIDANCE REAFFIRMED - Worldwide Net Sales of XTANDI Totaled $547 Million in the First Quarter of 2016 (+53% vs. Prior Year) - - First Quarter 2016 U.S. XTANDI Unit Demand Increased 33% vs. Prior Year and 7% vs Q4 2015 - - First Quarter 2016 U.S. XTANDI Net Sales of $307.6 Million (+37% vs. Prior Y |
|
| May 5, 2016 |
MEDIVATION REITERATES REJECTION OF SANOFI’S SUBSTANTIALLY INADEQUATE PROPOSAL EX-99.2 Exhibit 99.2 MEDIVATION REITERATES REJECTION OF SANOFI?S SUBSTANTIALLY INADEQUATE PROPOSAL SAN FRANCISCO, CA ? May 5, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today reiterated its rejection of Sanofi?s substantially inadequate proposal to acquire the Company for $52.50 per share in cash, following the receipt of a letter from Sanofi. Medivation notes that Sanofi?s letter simply restates an i |
|
| May 5, 2016 |
DEFA14A 1 d117265d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of inc |
|
| May 5, 2016 |
Medivation SANOFI DFAN14A 5-5-2016 DFAN14A 1 formdfan14a.htm SANOFI DFAN14A 5-5-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Prel |
|
| May 5, 2016 |
Exhibit 10.7 March 28, 2016 HAND DELIVERY Dear Mohammad, I am pleased to extend your role as Interim Chief Medical Officer. This extension will be from April 1, 2016 through June 30, 2016. Your role and duties will remain as communicated during the original interim assignment. During this period you will continue to report to me. We will meet regularly to discuss and plan your priorities and goals |
|
| May 5, 2016 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [], 20[] (the “Effective Date”) by and between Medivation, Inc., a Delaware corporation (the “Company”), and [], who serves as a director and/or an officer or agent of the Company (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals a |
|
| May 5, 2016 |
Separation Date Release (To be signed on or within 21 days after the Separation Date) mdvn-ex105_335.htm Exhibit 10.5 March 25, 2016 Sent Via Email Rick Bierly Re: Separation Agreement Dear Rick: This letter sets forth the terms of the separation agreement (the “Agreement”) between you and Medivation, Inc. (the “Company”) regarding your employment transition. 1.Separation Date; Final Pay. As discussed, your last day of employment and your employment termination date will be July 15 |
|
| May 5, 2016 |
Exhibit 10.6 March 25, 2016 Revised Jennifer Jarrett Email Delivery Dear Jennifer: It is my great pleasure to offer you the position of Chief Financial Officer, reporting to David Hung, President, and Chief Executive Officer. We are very excited about the possibility of you joining our team, and we look forward to the prospect of working with you in our innovative company! As an employee of Mediva |
|
| April 29, 2016 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF MEDIVATION, INC. (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 6 Section 7. Notice Of Mee |
|
| April 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No |
|
| April 29, 2016 |
mdvn-defr14a20160622.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| April 29, 2016 |
EX-99.2 Exhibit 99.2 Dear Team, I want to share some important news. A few minutes ago, we announced that our Board unanimously rejected Sanofi?s unsolicited proposal to acquire Medivation for $52.50 per share in cash. I encourage you to read our press release, which can be found here: http://investors.medivation.com/releases.cfm. Let me take a moment to explain how and why we concluded this propo |
|
| April 29, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE MEDIVATIONS BOARD OF DIRECTORS UNANIMOUSLY REJECTS SANOFIS UNSOLICITED PROPOSAL Opportunistically-Timed Proposal Substantially Undervalues Medivation and Is Not in the Best Interests of Stockholders SAN FRANCISCO, CA April 29, 2016 Medivation, Inc. (NASDAQ: MDVN) today announced that its Board of Directors, after consultation with its financial and |
|
| April 29, 2016 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 29, 2016 |
EX-99.2 3 d177084dex992.htm EX-99.2 Exhibit 99.2 Dear Team, I want to share some important news. A few minutes ago, we announced that our Board unanimously rejected Sanofi’s unsolicited proposal to acquire Medivation for $52.50 per share in cash. I encourage you to read our press release, which can be found here: http://investors.medivation.com/releases.cfm. Let me take a moment to explain how and |
|
| April 29, 2016 |
DEFA14A 1 d177084d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incor |
|
| April 29, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE MEDIVATIONS BOARD OF DIRECTORS UNANIMOUSLY REJECTS SANOFIS UNSOLICITED PROPOSAL Opportunistically-Timed Proposal Substantially Undervalues Medivation and Is Not in the Best Interests of Stockholders SAN FRANCISCO, CA April 29, 2016 Medivation, Inc. (NASDAQ: MDVN) today announced that its Board of Directors, after consultation with its financial and |
|
| April 29, 2016 |
Medivation SANOFI DFAN14A 4-29-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2016 |
DEFA14A 1 mdvn-defa14a20160622.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Com |
|
| April 28, 2016 |
mdvn-def14a20160622.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as pe |
|
| April 28, 2016 |
MEDIVATION CONFIRMS RECEIPT OF UNSOLICITED PROPOSAL FROM SANOFI EX-99.1 Exhibit 99.1 MEDIVATION CONFIRMS RECEIPT OF UNSOLICITED PROPOSAL FROM SANOFI SAN FRANCISCO, CA ? April 28, 2016 ? Medivation, Inc. (NASDAQ: MDVN) (?Medivation? or the ?Company?) confirmed today that it has received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of Medivation common stock for $52.50 in cash. On April 15, 2016, Medivation?s Board of Direct |
|
| April 28, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No |
|
| April 28, 2016 |
Medivation SANOFI DFAN 14A 4-28-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) |
|
| March 28, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File No |
|
| March 10, 2016 |
Medivation FORM 8-K/A (Current Report/Significant Event) Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of |
|
| March 9, 2016 |
Medivation 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| March 9, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE U.S. FDA LIFTS PARTIAL CLINICAL HOLD ON MEDIVATION?S PIDILIZUMAB ? Potentially Pivotal Phase II Trial in DLBCL and Other Studies May Proceed ? SAN FRANCISCO, CA, March 9, 2016 ? Medivation, Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the Investigational New Drug (IND) applica |
|
| February 26, 2016 |
S-8 As filed with the Securities and Exchange Commission on February 26, 2016 Registration No. |
|
| February 26, 2016 |
Medivation 10-K (Annual Report) mdvn-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to . Commission file number: 001-32836 ME |
|
| February 26, 2016 |
Exhibit 10.51 Medivation, Inc. Amended and Restated 2004 Equity Incentive Award Plan Performance Share Unit Grant Notice Medivation, Inc. (the “Company”), pursuant to its Amended and Restated 2004 Equity Incentive Award Plan, as amended from time to time (the “Plan”), hereby awards to Participant a Performance Share Unit award for the number of performance share units (“Share Units”) set forth bel |
|
| February 26, 2016 |
Medivation, Inc. Amended and Restated 2004 Equity Incentive Award Plan Restricted Stock Grant Notice Exhibit 10.9 Medivation, Inc. Amended and Restated 2004 Equity Incentive Award Plan Restricted Stock Grant Notice Medivation, Inc. (the “Company”), pursuant to its Amended and Restated 2004 Equity Incentive Award Plan, as amended from time to time (the “Plan”), hereby awards to Participant a Restricted Stock award for the number of shares of Stock set forth below (the “Award”). The Award is subjec |
|
| February 26, 2016 |
Exhibit 10.23 SUPPLEMENTAL AGREEMENT REGARDING CDX AGREEMENT AND COLLABORATION AGREEMENT AND SIXTH AMENDMENT TO COLLABORATION AGREEMENT This Supplemental Agreement Regarding CDx Agreement and Collaboration Agreement And Sixth Amendment to Collaboration Agreement (this “Supplemental Agreement”) is entered into as of January 6, 2016 (the “Effective Date”) by and among Medivation, Inc., a Delaware co |
|
| February 26, 2016 |
Exhibit 10.8 Medivation, Inc. Amended and Restated 2004 Equity Incentive Award Plan Restricted Stock Unit Grant Notice Medivation, Inc. (the “Company”), pursuant to its Amended and Restated 2004 Equity Incentive Award Plan, as amended from time to time (the “Plan”), hereby awards to Participant a Restricted Stock Unit award for the number of stock units (“Stock Units”) set forth below (the “Award” |
|
| February 26, 2016 |
EX-10.33 10 mdvn-ex1033543.htm EX-10.33 Exhibit 10.33 EXECUTION COPY AMENDMENT NO. 1 Dated as of November 13, 2015 to AMENDED AND RESTATED CREDIT AGREEMENT Dated as of October 23, 2015 THIS AMENDMENT NO. 1 (this “Amendment”) is made as of November 13, 2015 by and among Medivation, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPM |
|
| February 26, 2016 |
FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 Exhibit 10.16 FIFTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 This Fifth Amendment to Exclusive License Agreement (“Fifth Amendment”), dated as of October 21, 2009, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeut |
|
| February 26, 2016 |
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 Exhibit 10.14 THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 This Third Amendment to Exclusive License Agreement (“Third Amendment”), dated as of June 12, 2006, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics |
|
| February 26, 2016 |
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 Exhibit 10.12 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeuti |
|
| February 26, 2016 |
Exhibit 10.15 Fourth Amendment To Exclusive License Agreement Between The Regents of the University of California and Medivation, Inc and Medivation Prostate Therapeutics, Inc For UC Agreement Control No. 2006-04-0085 FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 This Fourth Amendment to Exclusive License Agreement (“Fourth Amendment”), dated as of July 17, |
|
| February 26, 2016 |
Subsidiaries of Medivation, Inc. Exhibit 21.1 Subsidiaries of Medivation, Inc. 1. Medivation Neurology, Inc. (Delaware) 2. Medivation Prostate Therapeutics, Inc. (Delaware) 3. Medivation Technologies, Inc. (Delaware) 4. Medivation Field Solutions, Inc. (Delaware) 5. Medivation Services, Inc. (Delaware) |
|
| February 26, 2016 |
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 Exhibit 10.13 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 This Second Amendment to Exclusive License Agreement (“Second Amendment”), dated as of May 8 , 2006, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeuti |
|
| February 26, 2016 |
Exhibit 10.50 January 6, 2016 Marion E. McCourt [Address] Dear Marion: It is my great pleasure to offer you the position of Chief Operating Officer, reporting to David Hung, President, and Chief Executive Officer. We are very excited about the possibility of you joining our team, and we look forward to the prospect of working with you in our innovative company! As an employee of Medivation Inc., ( |
|
| February 25, 2016 |
EX-99.1 Exhibit 99.1 Contacts: Rick Bierly Anne Bowdidge Chief Financial Officer Senior Director, Investor Relations (415) 543-3470 (650) 218-6900 MEDIVATION REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS AND PROVIDES 2016 FINANCIAL GUIDANCE Full Year 2015 Non-GAAP Collaboration Revenue $695.4 Million (+79% vs. Prior Year); Full Year 2015 Non-GAAP Net Income $170.0 Million, or $1.01 p |
|
| February 25, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d133593d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorp |
|
| February 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| February 10, 2016 |
MDVN / Medivation, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 medivationinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Medivation Inc Title of Class of Securities: Common Stock CUSIP Number: 58501N101 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate box to designate the rule pursuant to which |
|
| January 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| January 25, 2016 |
EX-99.1 2 d131505dex991.htm EX-99.1 David Hung, M.D. Founder, President and CEO January 25-29, 2016 NASDAQ: MDVN Exhibit 99.1 Safe Harbor This presentation includes forward-looking statements concerning our business plans and prospects that are made pursuant to the safe harbor provisions of the federal securities laws. Forward-looking statements are any statements regarding future events or result |
|
| January 25, 2016 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commiss |
|
| January 11, 2016 |
EX-99.1 David Hung, M.D. Founder, President and CEO JP Morgan Healthcare Conference | January 11, 2016 NASDAQ: MDVN Exhibit 99.1 Safe Harbor This presentation includes forward-looking statements concerning our business plans and prospects that are made pursuant to the safe harbor provisions of the federal securities laws. Forward-looking statements are any statements regarding future events or res |
|
| January 11, 2016 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2016 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commissi |
|
| December 18, 2015 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note Description of the Transaction On August 21, 2015, Medivation, Inc. (the Company) entered into an Asset Purchase Agreement (the Agreement) with BioMarin Pharmaceutical Inc. (BioMarin) pursuant to which the Company acquired all rights to talazoparib (talazoparib research program), an orally available |
|
| December 18, 2015 |
EX-99.1 Exhibit 99.1 TALAZOPARIB RESEARCH PROGRAM (A RESEARCH PROGRAM OF BIOMARIN PHARMACEUTICAL INC.) FINANCIAL STATEMENTS For the two years ended December 31, 2014 TALAZOPARIB RESEARCH PROGRAM (A RESEARCH PROGRAM OF BIOMARIN PHARMACEUTICAL INC.) FINANCIAL STATEMENTS TABLE OF CONTENTS Page FINANCIAL STATEMENTS Independent Auditors? Report 3 Balance Sheets as of December 31, 2014 and 2013 4 Statem |
|
| December 18, 2015 |
EX-99.2 Exhibit 99.2 TALAZOPARIB RESEARCH PROGRAM (A RESEARCH PROGRAM OF BIOMARIN PHARMACEUTICAL INC.) FINANCIAL STATEMENTS (UNAUDITED) For the nine months ended September 30, 2015 and 2014 TALAZOPARIB RESEARCH PROGRAM (A RESEARCH PROGRAM OF BIOMARIN PHARMACEUTICAL INC.) FINANCIAL STATEMENTS TABLE OF CONTENTS Page FINANCIAL STATEMENTS Balance Sheets as of September 30, 2015 (Unaudited) and Decembe |
|
| December 18, 2015 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation |
|
| December 7, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| November 6, 2015 |
EX-99.1 Exhibit 99.1 CureTech Ltd. ANNUAL REPORT 2013 CureTech Ltd. ANNUAL REPORT 2013 TABLE OF CONTENTS Page REPORT OF INDEPENDENT AUDITORS 2 FINANCIAL STATEMENTS IN NEW ISRAELI SHEKELS (NIS): Statements of financial position 3 Statements of income 4 Statements of comprehensive income (loss) 5 Statements of changes in equity (capital deficiency) 6 Statements of cash flows 7 Notes to financial sta |
|
| November 6, 2015 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commis |
|
| November 6, 2015 |
EX-99.2 Exhibit 99.2 CureTech Ltd. INTERIM FINANCIAL INFORMATION (Unaudited) AT SEPTEMBER 30, 2014 CureTech Ltd. INTERIM FINANCIAL INFORMATION (Unaudited) AT SEPTEMBER 30, 2014 TABLE OF CONTENTS Page CONDENSED FINANCIAL STATEMENTS (Unaudited) ? IN NIS: Statements of financial position 2 Statements of income 3 Statements of comprehensive income 4 Statements of changes in equity (capital deficiency) |
|
| November 6, 2015 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note Description of Transaction On October 23, 2014, Medivation, Inc. (the ?Company?) entered into a License Agreement with CureTech, Ltd. (?CureTech?) pursuant to which the Company could acquire an exclusive license to the worldwide rights to CureTech?s late-stage clinical molecule, pidilizumab (?MDV930 |
|
| November 6, 2015 |
License Agreement Medivation, Inc. CureTech Ltd. Dated as of October 23, 2014 LICENSE AGREEMENT EX-2.1 Exhibit 2.1 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. License Agreement between Medivation, Inc. and CureTech Ltd. Dated as of October 23, 2014 LICENSE AGREEMENT This License Agreement (thi |
|
| November 5, 2015 |
EX-99.1 Exhibit 99.1 Medivation Contacts: Rick Bierly Anne Bowdidge Chief Financial Officer Senior Director, Investor Relations (415) 543-3470 (650) 218-6900 MEDIVATION REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Third Quarter Non-GAAP Collaboration Revenue $190.1 Million (+79% vs. Prior Year); Third Quarter Non-GAAP Net Income $58.4 Million, or $0.35 per Diluted Share Third Quarter GAAP Collabor |
|
| November 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commiss |
|
| October 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| October 26, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission F |
|
| October 26, 2015 |
EX-10.1 Exhibit 10.1 EXECUTION COPY AMENDED AND RESTATED CREDIT AGREEMENT dated as of October 23, 2015 among MEDIVATION, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent and CITIBANK, N.A. as Syndication Agent and BANK OF AMERICA, N.A., BARCLAYS BANK PLC and MUFG UNION BANK, N.A. as Co-Documentation Agents J.P. MORGAN SECURITIES LLC and CITIGROUP GLOBAL MARKETS I |
|
| October 7, 2015 |
EX-2.1 2 d99291dex21.htm EX-2.1 Exhibit 2.1 CONFIDENTIAL Execution Copy [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. ASSET PURCHASE AGREEMENT BY AND BETWEEN BioMarin Pharmaceutical Inc. AND Medivation, |
|
| October 7, 2015 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commissi |
|
| September 29, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commi |
|
| September 18, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commi |
|
| September 9, 2015 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of September 4, 2015 among MEDIVATION, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent J.P. MORGAN SECURITIES LLC as Sole Bookrunner and Sole Lead Arranger TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Classification of Loans and Borrowings 33 SECTION 1. |
|
| September 9, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File |
|
| August 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 24, 2015 |
Exhibit 99.1 Exhibit 99.1 Medivation Contact BioMarin Pharmaceutical Contacts Anne Bowdidge Investors: (650) 218-6900 Traci McCarty (415) 455-7558 Media: Debra Charlesworth (415) 455-7451 Medivation to Expand Global Oncology Franchise with the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a potent PARP inhibitor, from BioMarin - Talazoparib is a Highly-Potent PARP Inhibitor in Phas |
|
| August 6, 2015 |
EX-99.1 Exhibit 99.1 Medivation Contacts: Rick Bierly Chief Financial Officer (415) 543-3470 Anne Bowdidge Senior Director, Investor Relations (650) 218-6900 MEDIVATION REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Raises Full-Year 2015 Non-GAAP Collaboration Revenue Guidance Second Quarter Non-GAAP Collaboration Revenue $174.8 Million (+114% vs. Prior Year); Second Quarter Non-GAAP Net Income $48 |
|
| August 6, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| June 19, 2015 |
Medivation FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| June 19, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
|
| June 19, 2015 |
EX-99.1 Exhibit 99.1 NOTICE OF FULL REDEMPTION MEDIVATION, INC. 2.625% Convertible Senior Notes due 2017 (the ?Notes?) CUSIP No. 58501N AA9 NOTICE IS HEREBY GIVEN TO THE HOLDERS of the above-referenced Notes Pursuant to Section 6.03 of the Indenture, dated as of March 19, 2012 (as modified by that certain First Supplemental Indenture dated March 19, 2012, the ?Indenture?; capitalized terms used an |
|
| June 19, 2015 |
MEDIVATION TO REDEEM OUTSTANDING CONVERTIBLE NOTES DUE 2017 EX-99.2 Exhibit 99.2 Medivation Contacts Rick Bierly Chief Financial Officer (415) 543-3470 Anne Bowdidge Senior Director, Investor Relations (650) 218-6900 MEDIVATION TO REDEEM OUTSTANDING CONVERTIBLE NOTES DUE 2017 SAN FRANCISCO, CA ? June 19, 2015 ? Medivation, Inc. (Nasdaq: MDVN) today announced that it has issued a notice of redemption to redeem on July 24, 2015 all of its outstanding 2.625% |
|
| June 19, 2015 |
CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION MEDIVATION, INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF MEDIVATION, INC. MEDIVATION, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: FIRST: The name of the Corporation is Medivation, Inc. (the ?Corporation?). SECOND: The date of filing of the original Certificate of Incorp |
|
| May 28, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2015 MEDIVATION, INC. (Exact name of registrant as specified in its charter) Delaware 001-32836 13-3863260 (State or other jurisdiction of incorporation) (Commission |
